Nitrofurantoin causes pulmonary fibrosis primarily through a chemical process called redox cycling, which floods lung tissue with damaging free radicals. Because the lungs are oxygen-rich, they are uniquely vulnerable to this type of injury. The damage can develop slowly over months or years of use, and roughly 16% of people who develop chronic lung changes from the drug experience progressive fibrosis even after stopping it.
Redox Cycling and Oxygen Radical Production
The core mechanism starts with how nitrofurantoin is metabolized inside cells. An enzyme called cytochrome P450 reductase transfers a single electron to nitrofurantoin, creating an unstable molecule known as a nitro radical anion. In the presence of oxygen, this radical is immediately converted back to the original nitrofurantoin molecule, releasing a byproduct: superoxide, a reactive oxygen species (ROS). The drug then cycles through this loop again and again, each pass generating more superoxide.
Superoxide doesn’t stay as superoxide for long. It quickly converts into hydrogen peroxide. When hydrogen peroxide encounters iron (which is naturally present in tissues), it produces hydroxyl radicals, some of the most destructive molecules in the body. This chain reaction is continuous as long as the drug is present and oxygen is available.
The lungs are the most oxygen-saturated tissue in the body, which is exactly why they take the hardest hit. Every breath supplies the molecular oxygen needed to keep the redox cycle spinning. The result is a buildup of free radicals that overwhelms the lungs’ natural antioxidant defenses.
How Free Radicals Damage Lung Tissue
These reactive oxygen species attack three critical components of lung cells. First, they destroy cell membranes through a process called lipid peroxidation, essentially breaking apart the fatty layers that hold cells together. Second, they alter proteins, causing them to lose function. Third, they damage DNA, which can trigger the cell to self-destruct or die outright. When enough cells in the lung lining are destroyed, the body responds with inflammation and, eventually, scar tissue formation. That scarring is fibrosis.
The immune system compounds the problem. Nitrofurantoin triggers immune activation alongside the direct oxidative damage. In chronic reactions, lung biopsies typically show a pattern called nonspecific interstitial pneumonia, meaning widespread inflammation in the tissue between the lung’s air sacs. Blood tests often reveal elevated inflammatory markers and sometimes positive autoimmune antibodies. Lung function tests show a restrictive pattern, meaning the lungs become stiff and cannot expand fully, with reduced ability to transfer oxygen into the bloodstream.
Acute Versus Chronic Lung Reactions
Nitrofurantoin causes two distinct patterns of lung injury, and they work through somewhat different pathways. The acute reaction typically appears about nine days into a course of treatment. It behaves more like an allergic or hypersensitivity response: sudden onset of fever, cough, and shortness of breath, often with eosinophils (a type of immune cell associated with allergic reactions) flooding the lungs. This acute form is not fibrosis. It usually resolves quickly once the drug is stopped.
The chronic reaction is the one that leads to fibrosis. It develops after months or years of continuous nitrofurantoin use, often in people taking it as long-term prophylaxis for recurrent urinary tract infections. The onset is insidious. Breathlessness and a dry cough creep in so gradually that patients and doctors often attribute them to aging or other conditions. By the time imaging reveals the damage, significant scarring may already be present. Chronic pulmonary reactions are 10 to 20 times less common than acute ones, but they carry far more serious consequences.
Who Is Most at Risk
Chronic lung toxicity from nitrofurantoin mainly affects older adults and those on prolonged courses of six months or longer. The overall incidence of serious pulmonary reactions is estimated at about 1 in 5,000 first-time prescriptions, but that figure includes the milder acute reactions. The chronic fibrotic pattern is much rarer.
Still, it is underrecognized. In one national adverse reaction database, 34% of all reported nitrofurantoin side effects involved the respiratory system, making the lungs the most commonly affected organ outside the intended urinary tract target. The gradual onset of symptoms means many cases are caught late, and monitoring practices remain inconsistent. Current prescribing guidelines recommend checking for respiratory symptoms and liver function during long-term use, but they don’t specify how often or by what method. Some medical advisory bodies recommend reviews at least every three to six months, including oxygen saturation checks and assessment of breathlessness.
Can the Damage Be Reversed?
The most important step is stopping nitrofurantoin as soon as lung toxicity is suspected. For many patients, this alone leads to meaningful recovery. In one study tracking patients after drug withdrawal, 61% showed complete resolution or only minimal residual fibrosis on follow-up imaging. About 23% showed no change, meaning their scarring stabilized but didn’t improve. The remaining 16% experienced progressive fibrosis despite stopping the drug.
Even imaging that initially looks alarming can sometimes improve. Two documented cases showed widespread scarring patterns on high-resolution CT scans that appeared to represent permanent fibrosis, yet follow-up scans after drug withdrawal revealed resolution of those changes. This suggests that some of what looks like established fibrosis on imaging is actually reversible inflammation or early-stage scarring that hasn’t yet become permanent.
The key variable is time. The longer someone takes nitrofurantoin after chronic lung injury begins, the more likely the damage becomes irreversible. Because symptoms develop so gradually, the window for full recovery often narrows before anyone realizes there’s a problem. This is why periodic monitoring of breathing symptoms matters for anyone on the drug long-term, particularly older adults taking it for UTI prevention.